Related Experiment Video

Updated: May 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

D A Sabbah1, M G Brattain, H Zhong

  • 1College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.

Current Medicinal Chemistry
|December 17, 2011
PubMed

Insights

This review explores dual and selective inhibitors targeting the phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR pathway for cancer therapy. It details drug design, clinical development, and structure-activity relationships for enhanced therapeutic outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR pathway is crucial for cell growth, proliferation, and angiogenesis, making it a key target in cancer treatment.
  • Inhibiting this pathway, either vertically or horizontally with other kinases, is a primary strategy in cancer chemotherapy to maximize therapeutic effects.

Purpose of the Study:

  • To review the drug design and clinical development of dual PI3K/mTOR inhibitors and mTOR-selective inhibitors.
  • To classify these inhibitors based on their mechanism of action and chemical structures.
  • To elucidate structural determinants for PI3Kα or mTOR selectivity and discuss combination therapies.

Main Methods:

  • Literature review of drug design and clinical development studies.
  • Classification of inhibitors by mechanism of action and chemical structure.
  • Analysis of structure-activity relationships to understand selectivity.

Main Results:

  • Discussion of dual PI3K/mTOR inhibitors and mTOR-selective agents.
  • Identification of structural features influencing selectivity for PI3Kα or mTOR.
  • Overview of current clinical trials involving combination therapies targeting the PI3K/AKT/mTOR pathway.

Conclusions:

  • Dual and selective inhibitors of the PI3K/AKT/mTOR pathway represent a significant advancement in cancer chemotherapy.
  • Understanding structure-activity relationships is key to developing more selective and effective inhibitors.
  • Combination therapies hold promise for improving treatment outcomes in various cancers.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...